The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity
Open accessAbstract
The high prevalence of pre-existing immunity to adenovirus serotype 5 (Ad5) in human populations may substantially limit the immunogenicity and clinical utility of recombinant Ad5 vector-based vaccines for HIV-1 and other pathogens. A potential solution to this problem is to use vaccine vectors derived from adenovirus (Ad) serotypes that are rare in humans, such as Ad35. However, cross-reactive immune responses between heterologous Ad serotypes have been described and could prove a major limitation of this strategy. In particular, the extent of immunologic cross-reactivity between Ad5 and Ad35 has not previously been determined. In this study we investigate the impact of pre-existing anti-Ad5 immunity on the immunogenicity of candidate rAd5 and rAd35 vaccines expressing SIV Gag in mice. Anti-Ad5 immunity at levels typically found in humans dramatically blunted the immunogenicity of rAd5-Gag. In contrast, even high levels of anti-Ad5 immunity did not substantially suppress Gag-specific cellular immune responses elicited by rAd35-Gag. Low levels of cross-reactive Ad5/Ad35-specific CD4+ T lymphocyte responses were observed, but were insufficient to suppress vaccine immunogenicity. These data demonstrate the potential utility of Ad35 as a candidate vaccine vector that is minimally suppressed by anti-Ad5 immunity. Moreover, these studies suggest that using Ad vectors derived from immunologically distinct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-existing anti-Ad immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 2×
“Tetrameric D/AL11 complexes were constructed essentially as previously described (4, 19) and were used to quantitate the emergence of AL11-specific CD8 T lymphocyte responses elicited by rAd5-Gag and rAd35-Gag in mice with or without anti-Ad5 immunity.”
MethodSelf-citationIsolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102
Shiver, J. W., Fu, T.-M., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z.-Q., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,176
Self-citationCD46 is a cellular receptor for group B adenoviruses
Gaggar, A., Shayakhmetov, D. M., & Lieber, A. (2003) · Nature Medicine · doi:10.1038/nm952 · Cited by 792
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z.-Y., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 663
Self-citationRoelvink, P. W., Lizonova, A., Lee, J. G. M., Li, Y., Bergelson, J. M., Finberg, R. W., Brough, D. E., Kovesdi, I., & Wickham, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.7909-7915.1998 · Cited by 654
Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de Béthune, M.-P., Kostense, S., Penders, G., Helmus, N., Koudstaal, W., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8263-8271.2003 · Cited by 467
Self-citationRoelvink, P. W., Lee, G. M., Einfeld, D. A., Kovesdi, I., & Wickham, T. J. (1999) · Science · doi:10.1126/science.286.5444.1568 · Cited by 406
Casimiro, D. R., Chen, L., Fu, T.-M., Evans, R. K., Caulfield, M. J., Davies, M.-E., Tang, A., Chen, M., Huang, L., Harris, V., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.11.6305-6313.2003 · Cited by 400
Replication-Defective Vector Based on a Chimpanzee Adenovirus
Farina, S. F., Gao, G.-P., Xiang, Z. Q., Rux, J. J., Burnett, R. M., Alvira, M. R., Marsh, J., Ertl, H. C. J., & Wilson, J. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.23.11603-11613.2001 · Cited by 272
Cited by
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
Adenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669
Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503
Self-citationHexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006) · Nature · doi:10.1038/nature04721 · Cited by 491
Self-citationImmune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
Liu, J., O’Brien, K. L., Lynch, D. M., Simmons, N. L., La Porte, A., Riggs, A. M., Abbink, P., Coffey, R. T., Grandpre, L. E., Seaman, M. S., et al. (2009) · Nature · doi:10.1038/nature07469 · Cited by 452
Self-citationChallenges in the development of an HIV-1 vaccine
Barouch, D. H. (2008) · Nature · doi:10.1038/nature07352 · Cited by 380
Self-citationSumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., Peter, T., Peyerl, F. W., Kishko, M. G., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7179 · Cited by 369
Self-citationStanley, D. A., Honko, A. N., Asiedu, C., Trefry, J. C., Lau-Kilby, A. W., Johnson, J. C., Hensley, L., Ammendola, V., Abbate, A., Grazioli, F., et al. (2014) · Nature Medicine · doi:10.1038/nm.3702 · Cited by 350
Self-citationQing, S., Lyu, C., Zhu, L., Pan, C., Wang, S., Li, F., Wang, J., Yue, H., Gao, X., Jia, R., et al. (2020) · Advanced Materials · doi:10.1002/adma.202002085 · Cited by 309
Barouch, D. H., Kik, S. V., Weverling, G. J., Dilan, R., King, S. L., Maxfield, L. F., Clark, S., Ng’ang’a, D., Brandariz, K. L., Abbink, P., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.025 · Cited by 305
Self-citationAdenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
Mendonça, S. A., Lorincz, R., Boucher, P., & Curiel, D. T. (2021) · npj Vaccines · doi:10.1038/s41541-021-00356-x · Cited by 294
Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?
Fausther-Bovendo, H., & Kobinger, G. P. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29594 · Cited by 276
Mast, T. C., Kierstead, L., Gupta, S. B., Nikas, A. A., Kallas, E. G., Novitsky, V., Mbewe, B., Pitisuttithum, P., Schechter, M., Vardas, E., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2009.10.145 · Cited by 276
Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185
Rise of the RNA machines – self-amplification in mRNA vaccine design
Comes, J. D. G., Pijlman, G. P., & Hick, T. A. H. (2023) · Trends in Biotechnology · doi:10.1016/j.tibtech.2023.05.007 · Cited by 87
Circumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors
Lopez-Gordo, E., Podgorski, I. I., Downes, N., & Alemany, R. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.228 · Cited by 65
Metadata
- Authors
- Barouch, D. H., Pau, M. G., Custers, J. H. H. V., Koudstaal, W., Kostense, S., Havenga, M. J. E., Truitt, D. M., Sumida, S. M., Kishko, M. G., Arthur, J. C., Korioth-Schmitz, B., Newberg, M. H., Gorgone, D. A., Lifton, M. A., Panicali, D. L., Nabel, G. J., Letvin, N. L., & Goudsmit, J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-05
- Volume
- 172
- Issue
- 10
- Pages
- 6290-6297
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1924636867
- Cited by
- 383
- References
- 31
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.